Cytokinetics(US:CYTK) Newsfile·2025-11-13 20:19Core Viewpoint - A class action securities lawsuit has been filed against Cytokinetics, Incorporated, alleging securities fraud that affected shareholders between December 27, 2023, and May 6, 2025 [2]. Group 1: Lawsuit Details - The lawsuit claims that Cytokinetics made materially false and misleading statements regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten [3]. - Defendants indicated that they expected FDA approval for aficamten's NDA in the second half of 2025, based on a PDUFA date of September 26, 2025, while failing to disclose risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) [3][4]. - During an earnings call on May 6, 2025, it was disclosed that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [4]. Group 2: Impact on Shareholders - As a result of the alleged false statements, shareholders purchased Cytokinetics' common stock at inflated prices and incurred significant losses when the truth about the NDA submission was revealed [5]. - Shareholders who suffered losses during the relevant timeframe are encouraged to seek recovery, with no cost or obligation to participate [6]. Group 3: Legal Representation - Levi & Korsinsky LLP, a nationally recognized securities litigation firm, has a strong track record in securing recoveries for shareholders and has been ranked among the top securities litigation firms in the United States for seven consecutive years [7].